146 related articles for article (PubMed ID: 4192759)
1. [Evolution of immunoglobulins IgA, IgM, IgG and LATS during treatment of hyperthyroidism with carmibazole and radioiodine].
Mahaux JE; Delcourt R; Nagel M; Chamla-Soumenkoff J; Levin S
Ann Endocrinol (Paris); 1970; 31(2):314-23. PubMed ID: 4192759
[No Abstract] [Full Text] [Related]
2. Studies on the antigen reacting with the thyroid-stimulating immunoglobulin (LATS) in thyrotoxicosis.
Benhamou-Glynn N; el-Kabir DJ; Roitt IM; Doniach D
Immunology; 1969 Feb; 16(2):187-204. PubMed ID: 4181510
[TBL] [Abstract][Full Text] [Related]
3. What is the antibody specificity of LATS?
Fagraeus A; Jonsson J; el-Kabir DJ
J Clin Endocrinol Metab; 1970 Oct; 31(4):445-7. PubMed ID: 4916544
[No Abstract] [Full Text] [Related]
4. Serum immunoglobulin levels in thyroid disease.
Glynne A; Thomson JA
Clin Exp Immunol; 1972 Sep; 12(1):71-8. PubMed ID: 4628405
[TBL] [Abstract][Full Text] [Related]
5. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
Hardisty CA; Hanford L; Humphries H; Munro DS
Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
[TBL] [Abstract][Full Text] [Related]
6. Specific and nonspecific responses in the bioassay of long-acting thyroid stimulator (LATS).
Chopra IJ; Solomon DH; Limberg NP
J Clin Endocrinol Metab; 1970 Oct; 31(4):382-90. PubMed ID: 5468701
[No Abstract] [Full Text] [Related]
7. Hyperthyroidism.
Kendall-Taylor P
Br Med J; 1972 May; 2(5809):337-41. PubMed ID: 4112238
[No Abstract] [Full Text] [Related]
8. LATS-protector activity in thyrotoxicosis measured by thyroidal intracellular colloid droplet formation.
Shishiba Y; Miyachi Y; Takaishi M; Ozawa Y
J Clin Endocrinol Metab; 1978 May; 46(5):841-8. PubMed ID: 262769
[TBL] [Abstract][Full Text] [Related]
9. The effect of radioiodine and antithyroid drugs on serum long acting thyroid stimulator protector (IATS-P). A three year prospective study.
Hardisty CA; Fowles A; Munro DS
Clin Endocrinol (Oxf); 1984 May; 20(5):597-605. PubMed ID: 6547647
[TBL] [Abstract][Full Text] [Related]
10. Humoral immunity and autoimmune disease.
Roitt IM
Vox Sang; 1969 Apr; 16(4):341-4. PubMed ID: 4184411
[No Abstract] [Full Text] [Related]
11. Immunoglobulin levels and long-acting thyroid stimulator (LATS) in hyperthyroidism. A preliminary study.
Yamakido M; Yokoyama M; Noguchi S
Hawaii Med J; 1969; 29(2):118-9. PubMed ID: 5361480
[No Abstract] [Full Text] [Related]
12. The nucleic acid content of lymphocytes in thyrotoxicosis.
Smith JF; Glen AC; Greig WR
Clin Exp Immunol; 1971 Jun; 8(6):911-6. PubMed ID: 5104635
[TBL] [Abstract][Full Text] [Related]
13. Long-acting thyroid stimulator (LATS) in hyperthyroidism and exophthalmos.
Friis T
Dan Med Bull; 1969 Nov; 16(10):294-304. PubMed ID: 5392781
[No Abstract] [Full Text] [Related]
14. Studies of immune mechanisms in leprosy. II Quantitative relationships of IgG, IgA, and IgM immunoglobulins.
Bullock WE; Ho MF; Chen MJ
J Lab Clin Med; 1970 May; 75(5):863-70. PubMed ID: 4192266
[No Abstract] [Full Text] [Related]
15. Long-acting thyroid stimulator in euthyroid relatives of thyrotoxic patients.
Wall JR; Good BF; Hetzel BS
Lancet; 1969 Nov; 2(7629):1024-6. PubMed ID: 4187540
[No Abstract] [Full Text] [Related]
16. Thyroid suppression and the long-acting thyroid stimulator following radioactive iodine therapy for thyrotoxicosis.
Alford FP; Larkins RG; Martin FI
Aust N Z J Med; 1971 Nov; 1(4):339-45. PubMed ID: 5292990
[No Abstract] [Full Text] [Related]
17. [Chronic thrombopenic purpura. Hyperthyroidism, pretibial myxedema and L.A.T.S].
Cattan D; Caen J; Fernandez Y; Izard J; Leclere H; Tanguy A; Lemenager J
Presse Med (1893); 1970 Jul; 78(35):1535-40. PubMed ID: 5464336
[No Abstract] [Full Text] [Related]
18. [Human thyroid stimulator (HTS) in thyroid diseases].
Hu ZY
Zhonghua Nei Ke Za Zhi; 1984 Aug; 23(8):480-3, 525. PubMed ID: 6548953
[No Abstract] [Full Text] [Related]
19. [Long-acting thyroid stimulator (LATS) in thyroid gland diseases and its relationship to the thyroid gland antibodies].
Weissbecker L; Uthgenannt H; Schemmel K; Müller W; Heesen H; Eickenbusch W; Bindeballe W
Schweiz Med Wochenschr; 1967 Jul; 97(28):898-904. PubMed ID: 5587446
[No Abstract] [Full Text] [Related]
20. The prediction of relapse after drug treatment of Graves' disease by assay of long acting thyroid stimulator-protector (LATS-P).
Hardisty CA; Hanford L; Munro DS
Clin Endocrinol (Oxf); 1981 May; 14(5):509-17. PubMed ID: 6895487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
